Altimmune to Present Pemvidutide Data at AASLD 2026
Altimmune will present 48-week IMPACT Phase 2b analyses and preclinical data on pemvidutide, including fibrosis-marker reductions, GI tolerability and reduced alcohol intake in a hamster model.
Altimmune will present 48-week IMPACT Phase 2b analyses and preclinical data on pemvidutide, including fibrosis-marker reductions, GI tolerability and reduced alcohol intake in a hamster model.